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Abstract
Aberrant changes in specific glycans have been shown to be associated with immunosurveillance, tumorigenesis,
tumor progression and metastasis. In this study, the N-glycan profiling of membrane proteins from human breast
cancer cell lines and tissues was detected using modified DNA sequencer-assisted fluorophore-assisted
carbohydrate electrophoresis (DSA-FACE). The N-glycan profiles of membrane proteins were analyzed from 7 breast
cancer cell lines and MCF 10A, as well as from 100 pairs of breast cancer and corresponding adjacent tissues. The
results showed that, compared with the matched adjacent normal tissue samples, two biantennary N-glycans (NA2
and NA2FB) were significantly decreased (p <0.0001) in the breast cancer tissue samples, while the triantennary
glycan (NA3FB) and a high-mannose glycan (M8) were dramatically increased (p = 0.001 and p <0.0001,
respectively). Moreover, the alterations in these specific N-glycans occurred through the oncogenesis and
progression of breast cancer. These results suggested that the modified method based on DSA-FACE is a high-
throughput detection technology that is suited for analyzing cell surface N-glycans. These cell surface-specific N-
glycans may be helpful in recognizing the mechanisms of tumor cell immunologic escape and could be potential
targets for new breast cancer drugs.
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Introduction
Breast cancer is the commonest cancer and the leading
cause of cancer death in women. It is well known that early
detection and diagnosis could dramatically improve breast
cancer patient 5-year survival rates [1]. At present, several
approaches, such as mammography, have been applied in
breast cancer diagnosis. However, these common diagnostic
approaches show unsatisfactory performance in sensitivity and
specificity. Therefore, there is an urgent need to find effective
biomarkers for breast cancer diagnosis. Over the past few
years, several large-scale proteomic studies have been carried
out to characterize the proteome of breast cancer to identify
biomarkers [2–4]. However, this strategy leads to complex data
sets, which make it hard to predict sensitive and specific
targeted proteins in breast cancer.
Glycomics has recently garnered much attention.
Glycosylation is the most complex post-translational
modification step in the biosynthesis process of proteins. A
particular type of N-glycans is closely associated with the
biological functions of cells [5,6], such as the growth,
differentiation, adhesion and metastasis. The sugar chains of
glycoproteins are important for maintaining the ordered “social
behavior” of differentiated cells in multicellular organisms.
Furthermore, alterations of the sugar chains also contribute to
the molecular mechanisms of abnormalities such as
inflammation, invasion and metastasis of tumor cells [7].
Actually, some studies have shown that several specific types
of glycan epitopes are closely associated with many types of
cancer [8,9]. However, there is still much to be understood
since the research on glycomics still falls behind that of
genomics and proteomics due to the complexity of
glycosylation at the molecular level and the lack of powerful
analytical tools.
Recently, matrix-assisted laser desorption/ionization-time-of-
flight mass (MALDI-TOF MS), high performance liquid
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chromatography (HPLC), lectin microarrays and DNA
sequencer-assisted fluorophore-assisted carbohydrate
electrophoresis (DSA-FACE) are the main methods for N-
glycome profiling and structural analysis, which constitute the
core of research in glycomics [10]. Among them, DSA-FACE
has been shown to be a robust, high-throughput, exceedingly
sensitive, and reliable quantitative method [11]. In DSA-FACE,
96-well plate-based sample preparation allows high-throughput
automatic analysis using multi-capillary separation and
facilitates exoglycosidase sequencing without the removal of
treated enzymes. This technique has been successfully applied
for screening serum glycoprotein biomarkers from healthy
people [12–15], patients suffering various diseases [16–21] and
cancer patients as well [22–27]. Our group also previously
investigated the relationship between human serum N-glycan
profiles and age and gender of healthy humans using DSA-
FACE [15]. However, to the best of our knowledge, the
application of this technique has yet to be demonstrated in the
analysis of cell surface-specific N-glycans from cells or tissue
specimens.
In this study, we modified the DSA-FACE technique to make
it suitable for analyzing the profiles of cell surface-specific N-
glycans from human breast cancer cell lines and tissues. Using
this modified method, we report the N-glycan profiles of 8 cell
lines and 100 pairs of matched normal and tumor tissues from
breast cancer patients. Our results indicate that the DSA-FACE
technique was also capable of detecting alterations in cell
surface-specific N-glycans from breast cancer cell lines and
tissues. The N-glycan profiles showed that peaks B1 (NA2) and
B4 (NA2FB) were significantly decreased, while peaks B2
(mannose 8, M8) and B5 (NA3FB) were significantly increased
in tumor samples in comparison with those of the control group.
The increased N-glycans could be regarded as potential
targets for drugs in tumor therapy, and the decreased N-
glycans would be beneficial in studying the relationship
between glycans and the immune evasion of cancer cells.
Meanwhile, knowledge of these specific N-glycans may help in
understanding the mechanisms of tumorigenesis, progression
and metastasis of breast cancer.
Materials and Methods
Specimens and cell culture
The Tumor Hospital of Harbin Medical University provided
100 pairs of matched adjacent normal and tumor specimens
from patients with histologically proven breast cancer, which
were frozen at -196oC before analysis. Board certified clinical
oncologists and pathologists carried out all clinical and
histological analysis of the biopsies. The stage was classified
according to the TNM criteria (2002) [28]. The use of human
breast tissues in this study was approved by the Ethical
Committee of the Tumor Hospital of Harbin Medical University,
and was in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki for research involving human
subjects. The written informed consents of all participating
subjects were obtained before commencement of the study.
Seven breast cancer cell lines SK-BR-3, MCF-7 and MDA-
MB-231 from breast adenocancer, T-47D and ZR-75-30 from
breast ductal cancer, Bcap37 from squamous cell cancer,
Hs-578T from mammary gland cancer and MCF 10A as a non-
tumorigenic epithelial cell line were used in this work. All cell
lines were purchased from American Type Culture Collection
(ATCC) with the exception of Bcap37, which was purchased
from the Shanghai Institute Cell Bank. All cell lines were
cultured according to supplier’s guidelines. For glycan analysis,
cells were detached using a cell scraper, washed with PBS,
pelleted and frozen at -80oC until analysis.
Preparation of membrane proteins
Membrane proteins from cell or tissue specimens were
extracted with a slightly modified detergent-based protein
extraction method adopted by Clark et al. [29]. In brief, 1×107
cells or 200 mg ground tissue specimens were collected and 1
mL ice-cold lysis buffer containing 100 mM Tris-HCl (pH 7.5), 1
mM EDTA, 2% Triton X-114 and 1% protease inhibitor mixture
(10 mg/mL PMSF, 2 mg/mL Leupeptin, 200 µg/mL Pepstatin, 2
mg/mL Aprotinin) was added. The cell lysate was centrifuged at
13,000 rpm for 20 min at 4oC to remove insoluble cell debris
and then an equal volume of sucrose cushion containing 6%
sucrose, 150 mM NaCl, 0.06% Triton X-114 and 10 mM Tris-
HCl was added to the supernatant, followed by incubation in a
37oC water bath for 5 min. After centrifugation, the supernatant
was discarded and 9-fold volume of acetone precooled at
-20oC was added to the detergent phase to precipitate protein.
Finally, after overnight incubation at -20oC, the acquired
membrane protein was collected by centrifugation at 13,000
rpm for 20 min at 4oC, dried in a vacuum, resuspended in 50 µL
deionized water and stored at -80oC.
The concentration of the membrane protein was determined
by Lowry assay [30]. Membrane proteins were identified by
Western blot using anti-Na+/K+ ATPase-α1 antibody (Santa,
U.S.) as the first antibody, and cytoplasmic proteins were
distinguished by anti-γ-tubulin antibody (Santa, U.S.). Signals
were developed with an enhanced chemiluminescence
Western blotting detection system (ECL kit, GE healthcare).
Preparation of N-glycans from membrane proteins
The preparation of N-glycans from membrane proteins was
composed of PNGase F digestion, GC resin purification,
removal of sialic acid, fluorescence labeling and Sephadex
G10 purification steps. In order to analyze the N-glycan
profiling of cell/tissue specimens, all the parameters involved in
above N-glycans preparation protocol which fit for DSA-FACE
analysis of serum specimens, especially the quantities of cell/
tissue specimens, enzymes and regents, were reset. In
addition, a GC resin purification process was introduced in
sample preparation to remove remaining polypeptides,
detergent, monosaccharides and salts from the digestion
mixture containing glycans. The modified protocol for the N-
glycans preparation process is as follows:
For the PNGase F (NEB, P0704L) digestion, 6 µL of
denaturing buffer containing 5% SDS and 10 mM NH4HCO3
(pH 8.3) were added to 15 µL of membrane proteins. Then, the
acquired suspension was heated at 95oC for 10 min, followed
by cooling at 4oC for 15 min. To release the N-glycans from the
proteins, 4 µL of PNGase F solution containing 500 units
Cell Surface N-Glycans of Breast Cancer
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PNGase F and 3.33% NP-40 were added to each tube followed
by incubation at 37oC overnight.
The released N-glycans were purified using non-porous
graphitized carbon resin (GC resin) from Carbograph [31] with
some modifications. Briefly, 40 mg of GC resin were loaded
into each well of a 96-well plate and pre-activated by 5 cycles
of washing with 200 µL washing buffer containing 80% (v/v)
acetonitrile and 0.1% trifluoroacetic acid (TFA) and then with
200 µL deionized water. During this process, the washing
buffer and deionized water were removed via centrifuging the
plate at 30 g for 5 min (Beckman, AllegraTM X-22 centrifuge).
After the addition of PNGase F reaction mixture obtained from
last step, each well on the plate was washed 5 times with 200
µL deionized water followed by centrifugation at 200 g for 20 s
to remove the remaining salts, monosaccharides and
detergent. Finally, N-glycans were sequentially eluted twice
with 200 µL elution buffer I (10% acetonitrile in H2O), elution
buffer II (20% acetonitrile), elution buffer III (25% acetonitrile,
0.05% TFA) and 3 times by 200 µL elution buffer IV (40%
acetonitrile, 0.05% TFA). The flow rate of centrifugation was
maintained at 0.5-1 mL/min. The elute with N-glycans was
collected in a 200 µL EP-tube and dried in a vacuum for further
use.
To remove sialic acid, the dried glycans were redissolved in
25 µL deionized water and mixed with a 12 µL neuraminidase
(NEB, P0720L) solution containing 30 units of neuraminidase,
3 µL G1 buffer and 8.4 µL H2O, and were incubated at 37oC
overnight.
To label the desialylated N-glycans with 8-amino-1, 3, 6-
pyrenetrisulfonic acid (APTS), the samples were dried
completely at 65oC for about 3 h, and after cooling they were
combined with 5 µL of APTS labeling buffer (1:1 of 20 mM
APTS in 1.2 M citric acid and 1 M NaCNBH3 in DMSO). The
tube was sealed and heated for 2 h at 90oC and this reaction
was stopped by adding 20 µL of water.
Finally, the labeled N-glycans were purified with Sephadex
G10 as previously described [11]. In brief, the sample was
loaded on the well of a Multiscreen-Durapore membrane-lined
96-well plate (Millipore) with 100 mg/well Sephadex G10 and
was eluted by 3 cycles of washing with 20 µL of deionized
water by centrifugation at 750 g for 10 s. The collective
samples were dried in a vacuum apparatus and were stored at
-20oC for further analysis.
Glycan analysis with a DNA sequencer
The resulting APTS-labeled glycans were dissolved in 15 µL
deionized water and 10 µL of the solution was dispensed into
the wells of a 96-well plate, which was loaded onto an ABI
3130 sequencer equipped with a standard 36 cm capillary
array filled with the POP-7 polyacrylamide linear polymer. The
running parameters for the sequencer were the same in the
previously described protocol [11]. The resultant
electropherograms were then analyzed using GeneMapper 4.0
software. Each structure of N-glycan was numerically
described by normalizing its height to the sum of the heights of
all peaks.
Structural analysis of the N-glycan pool using
exoglycosidase digestion
An appropriate number of APTS-labeled N-glycans, obtained
with the procedure described above, were digested overnight
with different mixtures of exoglycosidases in 10 mM NH4Ac (pH
5.0) at 37oC. The enzymes in use included Streptococcus
pneumoniae β-1, 4-galactosidase, bovine kidney α-1, 6-
fucosidase, almond meal α-1, 3/4-fucosidase and Aspergillus
saitoi α-1, 2-mannosidase. All enzymes were from Prozyme,
San Leandro, CA. DSA-FACE was used to analyze the
digestion products.
Statistical analysis
All quantitative variables were presented as mean ± SD.
Paired and unpaired t-tests were used for comparison of the
two tissue groups, and for comparison of more than two cell
line groups, a one-way ANOVA was applied. Pearson
coefficients of correlation (Spearman coefficients of correlation
were calculated for ordinal categorical variables) and their
associated probability (p) were used to evaluate the
relationship between parameters. All reported p values were
two-tailed, and p values <0.05 were considered statistically
significant. Statistical analyses were performed with SPSS10.0
software.
Results
Establishment of the method for analyzing N-glycan
profiles of membrane proteins from cell and tissue
specimens based on the DSA-FACE technique
As shown in Figure S1, the DSA-FACE technique was
modified to analyze the N-glycan profiles of membrane proteins
from human breast cancer cell and tissue specimens. First, the
membrane proteins of cell lines or tissues were isolated using a
modified detergent-based protein extraction method. The purity
of the obtained membrane proteins was confirmed by Western
blotting using anti-Na+/K+ ATPase-α1 and anti-γ-tubulin
antibodies (Figure 1A). In Figure 1A, Na+/K+ ATPase-α1 was
only present in the detergent phase of Bcap37 cell and tumor
tissue samples, but not in the liquid phase, which contained
cytoplasmic proteins. Therefore, the detergent phase of cell
and tissue samples contained mostly membrane proteins. This
result indicated that the detergent-based method was capable
of perfectly isolating membrane proteins from total proteins to
make membrane proteins suitable for the following analysis.
GC and Sephadex G10 resins were introduced as
purification agents to make N-glycans suitable for N-glycan
profiling. The GC resin is able to remove salts, detergent and
polypeptide contaminants from the crude N-glycans sample
while excessive APTS could be removed by Sephadex G10
resin. In this study, the GC resin purification step was further
optimized. Gradient elution was adopted to purify glycans in
which elution buffers I, II, III were successively used twice and
elution IV thrice. Meanwhile eluotropic centrifugation was
adjusted to keep the flow rate at 0.5-1.0 mL/min. Results
indicated that the quality of N-glycan profiling was remarkably
improved, especially in the peak numbers and relative heights
of glycans in comparison with that of the isocratic elution
Cell Surface N-Glycans of Breast Cancer
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method (25% ACN + 0.075% TFA) [31] and purification-free
method (Figure S2).
Using this modified method, we first compared the N-glycan
profiles of cytosolic and membrane proteins from breast cancer
cell line and tissue specimens. As shown in Figure 1B, the N-
glycan profiling of membrane proteins was dramatically
different from that of cytosolic proteins. Although more than 10
peaks were detected before DP8, most signal peaks (e.g., B1
to B5 as shown in Figure 2) were located from DP8 to DP12 in
N-glycan profiling of membrane proteins. These five peaks
(peak B1 to B5) were studied in the following studies because
(1) only the peaks falling the range of DP8-DP12 are
membrane-protein-specific; (2) all of them could be found in all
of breast cancer cell lines and tissues and also showed a high
fluorescent intensity. These results indicated that the modified
DSA-FACE technique could help with obtaining well separated
Figure 1.  Establishment of the DSA-FACE method for
analyzing N-glycan profiling in breast cancer.  (A) Equal
amounts (20 μg and 100 μg for cell line and tissue specimens,
respectively) of cytoplasmic and membrane proteins (CP and
MP) from Bcap 37 cells and tumor tissue were determined by
Western blotting using γ-tubulin and Na+/K+ ATPase-α1
antibody, respectively. Na+/K+ ATPase-α1 (an integral
membrane protein) and γ-tubulin (a core component of the
centrosome) were chosen as the cytomembrane and
cytoplasm markers, respectively. (B) The representative N-
glycan profiles of cytosolic and membrane proteins from cell
line (upper panel, n=8) and tissue (lower panel, n=200).
doi: 10.1371/journal.pone.0072704.g001
membrane proteins from cell line and tissue samples in the
sample preparation step, and to obtain better N-glycan profiling
(Figure 2).
Figure 2.  The representative N-glycan profiles of
membrane proteins from human breast cancer cell line
and tissue.  The desialylated N-glycan profiles of membrane
proteins from cell lines (n=8) and tumor tissues (n=100).
Oligomaltose is used as a sugar mass reference. The number
of glucose units (degree of polymerization, DP) in these
structures is indicated. N-glycan profiles from RNaseB and
serum were used as N-glycan profile controls. RNaseB
contained high mannose from M5 to M9. Serum contained
various complex N-glycans and the most abundant glycans
detected in serum are marked. The vertical axis represents the
glycan intensity of the peaks as a percent of the relative
fluorescence level. The X-axis represents the retention time of
the peaks. The N-glycan structures of the corresponding peaks
are shown below the panels. NGA2F is an agalacto core-α-1,
6-fucosylated biantennary glycan; NA2 is a bigalacto
biantennary glycan; NA2F is a bigalacto core-α-1, 6-
fucosylated biantennary glycan; NA2FB is a bigalacto core-α-1,
6-fucosylated bisecting biantennary glycan; NA3 is tri-
antennary; NA3FB is a core-α-1, 6-fucosylated triantennary
glycan. The symbols used in the structural formulas are as
follows: (○) β-linked N-acetylglucosamine; (●) β-linked
galactose; (□) α-linked mannose; (■) β-linked mannose; (▲)
α-1, 6-linked fucose.
doi: 10.1371/journal.pone.0072704.g002
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Structural analysis of N-glycans
RNaseB, a glycoprotein, carries multiple types of glycans,
most of which are high-mannose N-glycans. The structures of
these N-glycans such as M5-M9 (RNaseB was digested by
PNGase F) have been characterized [32,33]. While, the
structures of NGA2F to NA3FB were also revealed in the
glycoproteins from human serum [34]. In this study, in order to
determine the structures of the N-glycans from cell or tissue
samples, we compared their N-glycan profiles with that of
RNaseB and serum whose N-glycan profiles were already
known (Figure 2). Peaks B1, B4 and B5 migrated at the same
rates as NA2, NA2FB and NA3FB, respectively, in the
corresponding human serum N-glycan profile. The N-glycan
structures of these peaks were further studied by
exoglycosidase digestion (Figure 3A, lower panel). Two, two
and three galactoses could be removed from N-glycans
responding to peaks B1, B4 and B5, respectively, by β-1, 4-
galactosidase. When β-1, 4-galactosidase was combined with
α-1, 6-fucosidase, one extra fucose residue was taken off from
peaks B4 and B5. Nevertheless peaks B4 and B5 could not be
digested by α-1, 3/4-fucosidase. This suggested that peaks B4
and B5 were the substrates of α-1, 6-fucosidase but not α-1,
3/4-fucosidase. These results indicated that peak B5 was a
core-α-1, 6-fucosylated triantennary glycan (NA3FB).
Moreover, the motion trails of peaks B1 and B4 that had
undergone the digestion of β-1, 4-galactosidase or α-1, 6-
fucosidase, or their mixture, were consistent with those of the
reference glycans NA2 and NA2FB in human serum (Figure
3A, upper panel). In addition, we also found that peaks B2 and
B3 migrated at the same site as M8 and NA2F or M9,
respectively. Thus, the structures of peaks B2 and B3 were
confirmed as M8 and NA2, respectively, by α-1, 2-
mannosidase and a series of exoglycosidases as mentioned
above (Figure 3B and 3C). The structures of the N-glycans in
tumor cell lines were also found to be consistent with that in
tumor tissues (Figure S3). We therefore assigned the peaks
B1, B2, B3, B4 and B5 in the N-glycan profiles from breast
cancer cell lines or tissues as NA2, M8, NA2F, NA2FB and
NA3FB, respectively.
Alteration of the cell surface-specific N-glycans from
breast cancer cell lines
The N-glycan profiles of membrane proteins from cell lines
were obtained and analyzed using the above modified method.
Figure 4A displayed the N-glycan profiles of a non-tumorigenic
epithelial cell line MCF 10A and 7 breast cancer cell lines (SK-
BR-3, MCF-7, Bcap37, MDA-MB-231, T-47D, Hs-578T and
ZR-75-30). We compared the corresponding peaks in N-glycan
profiles of MCF 10A and each tumor cell line. Results showed
that peaks B1, B2 and B4 were significantly altered in most of
the tumor cell lines (Figure 4B, C and D). Peak B2, which
represented high mannose N-glycan (M8), was significantly
increased (Figure 4B) but peaks B1 (NA2) and B4 (NA2FB)
were significantly decreased in cancer cell lines in comparison
with MCF 10A. In particular, peak B4 (NA2FB) was completely
lost in Bcap37, MDA-MB-231 and Hs-578T cells (Figure 4C
and D).
Alteration of cell surface-specific N-glycans from
clinical breast cancer tissues
Based on the results of the cell lines, 100 pairs of N-glycan
profiles of membrane proteins from matched normal and
malignant tissues were isolated from breast cancer patients.
The N-glycans were represented by peaks B1-B5 which
corresponded to the cell lines.
The clinicopathological characteristics of breast cancer
specimens from the 100 patients are presented in Table 1.
Specimens were characterized according to the patients’ age,
lymph node metastasis, hormonal and HER-2 receptor status
and tumor grade according to TNM stages.
Paired and unpaired t-tests were used to compare the two
tissue groups and the intra- and inter-assay coefficients of
variations (CVs) of the glycan analysis were less than 5%.
Results showed that the N-glycan profiles of breast cancer
tissues were significantly distinguished from that of
corresponding adjacent tissues (Figure 5A). Peaks B1 (NA2)
and B4 (NA2FB) were significantly decreased in the tumor
group (p<0.0001) compared with the corresponding normal
tissue group, which was consistent with those in the cancer cell
lines (Figures 4B and 5B). Furthermore, peaks B2 (M8) and B5
(NA3FB) were significantly increased in the tumor group
(p<0.0001 and p=0.001) compared to the corresponding
normal tissue group (Figure 5B). These results indicated that
NA2, NA2FB, M8 and NA3FB were dramatically altered on the
surface of breast cancer cells.
Alteration of specific N-glycans in breast cancer
patients with different ages and clinical stages
The concentrations of biantennary glycans (NA2 and
NA2FB), a triantennary glycan (NA3FB) and a high-mannose
glycan (M8) in breast cancer patients with different ages and
clinical stages were compared to study the correlation between
these N-glycans and patient ages and clinical stages (Table 1).
Both peaks B1 (NA2) and B4 (NA2FB) from tumor tissue
specimens were significantly decreased in all ages (Figure 6A)
and clinical stage groups (Figure 6B) compared with
corresponding normal tissue specimens. Peak B2 (M8) was not
only significantly increased in all age and stage groups but also
significantly higher in tumors from patients >40 years of age.
These results suggested that the alterations of peaks B1
(NA2), B2 (M8) and B4 (NA2FB) are part of the oncogenic
process of breast cancer. It is worth noting that the alteration of
peak B5 (NA3FB) trended higher with age >40 and with >
stage I tumors. Although peak B5 (NA3FB) did not have a
statistically significant difference (p=0.057) relative to normal
tissues in stages III and IV tumors as compared to stage II
tumors, this is probably due to the limited number of specimens
analyzed. Based on this observation, we speculate that NA3FB
may be associated with malignant progression of breast
cancer.
Correlation between specific N-glycans and clinical
pathologic features
The correlation between N-glycans and hormone receptors,
the Her-2 receptor and lymph node metastasis (LN) status was
analyzed in breast cancer patients using Pearson correlation.
Cell Surface N-Glycans of Breast Cancer
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However, the results showed that NA2, NA2FB, M8 and
NA3FB were not closely correlated with the clinical pathologic
characteristics of the tumors (Table S1).
Discussion
Glycomics has grown to be a research hotspot due to the
awareness of the important biological functions of glycosylation
and rapid development of glycan researching approaches. In
the past decade, DSA-FACE, as an N-glycan profiling detection
technique, has drawn much attention due to its advantages
such as high sensitivity, high throughput and quick analysis. It
has been widely accepted as a biomarker screening approach
in cancer and other disease research. For instance, DSA-
FACE has been applied to identify serum protein biomarkers
for liver fibrosis (GlycoFibroTest) [20], hepatic cirrhosis
(GlycoCirrohTest) [35], hepatocellular cancer (GlycoHCCTest)
[34], Alzheimer’s disease [17] and colorectal cancer
(CRCglycoA/B) [27]. However, to our knowledge, there has
been no previous report on membrane protein N-glycan
profiling from tissues or cell lines obtained with DSA-FACE,
which could be a limitation of its further use in glycomics. In this
Figure 3.  The exoglycosidase sequencing of the membrane protein N-glycans from tumor tissues.  (A) Exoglycosidase
sequencing of N-glycans of membrane proteins from breast cancer tissue (lower panel) and glycoproteins from healthy human
serum as reference (upper panel) to verify the structures of peaks B1, B4 and B5. The structures of peaks B2 and B3 are confirmed
in (B) and (C), respectively. The total N-glycans were treated with single or combined exoglycosidase arrays as indicated in context.
The arrow lines indicate the changes in glycan peaks that underwent glycosidase digestion. The nomenclature of N-glycans and
symbolic representations correspond to those in Figure 2.
doi: 10.1371/journal.pone.0072704.g003
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study, we established a DSA-FACE-based method that was
optimized for the profiling of cell surface-specific N-glycans
from human breast cancer cell lines and tissues.
N-glycan profiles of membrane proteins from human breast
cancer cells and tissues were obtained with the modified DSA-
FACE method. It was found that the relative levels of NA2
(peak B1) and NA2FB (peak B4) in breast cancer groups were
dramatically decreased (p<0.0001) compared to corresponding
control groups. This indicated that NA2 and NA2FB were the
dramatically changed functional N-glycans on breast cancer
cell surfaces. Some previous studies reported that NA2 was
less abundant in hepatocellular cancer (HCC) patients with
hepatitis C virus (HCV) than in healthy humans [36] and
NA2FB was found to be significantly decreased in HCC
patients with HBV in comparison to those with cirrhosis [34].
Therefore, NA2 and NA2FB were closely associated with HCC
and probably breast cancer as well. It is well known that
glycans are not antigenic by themselves but are able to be
antigenic if they bond to large carrier molecules such as
proteins. Glycosylation contributes to antigen presentation and
the product-glycoprotein can be antigenic to elicit various anti-
carbohydrate antibodies [37]. Cancer cells are the altered-self
cells that have their own antigens. The immune system is able
to recognize and destroy cancer cells via recognizing the
tumor-specific antigens on cell surfaces. However, cancer cells
can successfully evade immunosurveillance via some
mechanisms include shedding and/or modulating antigens.
From this point of view, a decrease in the membrane
glycoproteins glycans enables cancer cells to mask or lose
antigenic epitopes, which consequentially leads to the
immunologic escape of tumor cells. Cormier et al. [38] found
the expression of melanoma-associated antigens (MAAs; a
glycoprotein on cell membranes) was decreased to 50% to
allow melanoma cells escape the recognition by HLA class I-
Figure 4.  The significantly changed N-glycans of the membrane proteins of human breast cancer cell lines.  (A) The
representative N-glycan profiles of membrane proteins from human breast cancer cell lines (n=7). MCF 10A: from breast fibrocystic
disease as a non-tumorigenic epithelial cell line; SK-BR-3, MCF-7, Bcap 37, MDA-MB-231, T-47D, Hs 578T and ZR-75-30: cancer
cell lines; Serum: from healthy humans. (B–D) The statistically significant difference in N-glycan peaks B1, B2, B4 and B5 between
MCF 10A and various cancer cell lines. Peak B2 is significantly increased in cancer cell lines compared with MCF 10A. On the
contrary, peaks B1 and B4 are dramatically decreased in cancer cell lines. Particularly, peak B4 is completely lost in Bcap 37, MDA-
MB-231 and Hs 578T cell lines. The percentages of each specific peak height in the total peak heights are expressed as mean ±
SD. Asterisks indicate statistically significant differences between the various cancer cell lines and the MCF 10A cell line (* p < 0.05,
** p < 0.01). Five major glycan peaks B1-B5 in normal control and breast cancer groups were detected. Experiments were repeated
three times.
doi: 10.1371/journal.pone.0072704.g004
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restricted cytotoxic T cells. In this study, the decreased cell
surface N-glycans NA2 and NA2FB may also be related to the
immunologic escape of breast cancer cells. Further study on
these altered N-glycans may provide a novel route to
demonstrate the immunologic escape mechanism of breast
cancer cells.
In addition, a branching α-1, 6-fucosylated triantennary
glycan, NA3FB (peak B5), was found to be significantly
increased in breast cancer patients. Also, this variation trend
for peak B5 was exactly consistent with that in breast cancer
serum (our unpublished data). Nakagawa et al. [39] also found
that NA3FB was increased in α-fetoproteins (AFPs) from HCC
by detecting the N-glycan structures of AFPs from cell lines,
serum and ascites fluids from HCC patients. These results are
consistent with our findings in breast cancer. The same
mechanism seems to regulate NA3FB in hepatocellular and
breast cancer cells and the change in NA3FB may be involved
in tumor progression. Lebrilla et al. [40] proposed that the
elevation of the high-mannose glycans probably was a
common phenomenon in breast cancer because they found the
level of M9 significantly increased in serum samples from
breast cancer in mice and humans. In this study, another high-
mannose, M8, was also found to be elevated on the cell
surface of breast cancer cells compared with normal cells.
Furthermore, M8 was not only significantly increased in the
patients of different ages and TNM stages but also gradually
increased with patient age until 60-years-old. To date, several
tumor-specific carbohydrates were increased by different
degrees and have been found be associated with breast
cancer and have been used in tumor therapy as targeted
antigens, such as Tn antigen, sialyl Lewis X antigen, MUC1
Table 1. Clinical Characteristics of the Study Population.
Characteristics Category Cases Percentage (%)
Age <=40 23 23.0
 41-50 32 32.0
 51-60 31 31.0
 >60 14 14.0
 Mean 49.8  
Metastasis LN b) 47 58.0
Hormone receptor ER c) (+) 46 68.7
 ER c) (-) 21 31.3
 ND a) 33  
 PR d) (+) 41 61.2
 PR d) (-) 26 38.8
 ND a) 33  
Her-2 Her-2 (3+) 5 8.7
 Her-2 (2+) 13 20.0
 Her-2 (+/-) 47 72.3
 ND a) 35  
TNM stage I 11 13.9
 II 41 51.9
 III-IV 27 34.2
 ND a) 21  
a) ND, not determined; b) LN, lymph node; c) ER, estrogen receptor; d) PR,
progesterone receptor.
glycoprotein, Her-2/Neu glycoprotein and CEA [41].
Consequently, the upregulated N-glycans NA3FB and M8 in
this study could serve as new potential breast cancer-specific
carbohydrate antigens. In the future, a new drug targeting
NA3FB or M8 holds the promise of being more selective for
cancer cells and harming fewer normal cells, therefore,
reducing side effects and improving quality of life.
Based on the N-glycan structure analysis, we inferred that
the alternations of biantennary glycan NA2, bisecting
biantennary glycan NA2FB and triantennary glycan NA3FB
could be attributed to the changed expression of two
glycosyltransferases GnT-III and GnT-V. Pawelek et al.
reported that the expression of GnT-V was strongly up-
regulated in breast cancer [42]. Thus, according this study,
Figure 5.  The significantly changed N-glycans in breast
cancer tissues compared to adjacent normal tissues.  (A)
The typical cell surface-specific N-glycan profiles from breast
cancer tissue (n=100) and adjacent normal tissue (n=100). (B)
The statistically significant differences of N-glycan peaks B1,
B2, B4 and B5 between breast cancer and adjacent normal
tissues. The statistically significant differences between groups
are indicated as p value. The structures of the N-glycan peaks
B1, B2, B4 and B5 are shown in the Figure 2.
doi: 10.1371/journal.pone.0072704.g005
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GnT-V which generates triantennary glycan NA3FB could
compete as a substrate with GnT-III which produces bisecting
GlcNAc (NA2FB). This leads to an increased abundance of
NA3FB and decreased abundance of NA2 and NA2FB during
tumor development in breast cancer patients (Figure 7).
Furthermore, it has been reported that the increased
triantennary glycans could result in aberrant N-glycosylation of
her-2 and/or the erbB family receptors in the oncogenesis and
progression of breast cancer [43]. This aberrant alteration of
the receptor family members on cell surfaces can regulate their
endocytosis and lead to the altered binding of ligands (e.g.,
EGF), which consequently affects the cancer signaling
pathways mediated by these receptors. From this point of view,
the significantly altered cell surface-specific N-glycans,
especially those from critical receptors on cell surfaces
regulated by various glycosyltransferases, are potential
participants in tumor progression in breast cancer.
Figure 6.  The significantly changed N-glycans in breast
cancer tissues according to age and clinical stage.  (A) The
correlation of cell surface specific N-glycans with four age
groups. (B) The correlation of cell-surface specific N-glycans
with clinical stages. Statistically significant differences between
groups is indicated by p value (* p < 0.05, ** p < 0.01). The
structures of N-glycan peaks B1, B2, B4 and B5 are shown in
Figure 2.
doi: 10.1371/journal.pone.0072704.g006
In conclusion, this study analyzed the cell surface-specific N-
glycans from cell line and tissue specimens of breast cancer
patients for the first time using a modified DSA-FACE
technique. It was found that the N-glycans NA2 and NA2FB
were significantly decreased in 100 human breast cancer
tissue samples compared with corresponding adjacent normal
tissue samples, while M8 and NA3FB were dramatically
increased. Moreover, the alterations of these specific changed
N-glycans were also found through the oncogenesis and
progression of breast cancer by a correlation analysis between
the N-glycan profiles of breast cancer tissue specimens and
patient ages and tumor clinical stages. These dramatically
changed N-glycans on tumor cell surfaces are not only
promising drug targets for breast cancer therapy but they also
help with understanding the mechanism of tumor cell
immunologic escape in breast cancer.
Supporting Information
Figure S1.  The workflow scheme of high-throughput
membrane protein N-glycan preparation and analysis
using a DNA sequencer.
(TIF)
Figure S2.  The N-glycan profiles of breast cancer cell lines
or tissues with different purification methods. (A) The N-
glycan profiling of 160 μg membrane proteins from breast
cancer cell line Bcap 37 without purification (upper profiling),
with relatively simple purification (middle profiling) and optimal
purification (lower profiling). (B) The N-glycan profiling of 160
μg membrane proteins from breast cancer tissue without
Figure 7.  The schematic presentation of changes in N-
linked glycans in breast cancer.  The increased
concentration of NA3FB (peak B5) and decreased
concentration of NA2 (peak B1) and NA2FB (peak B4) in
breast cancer tissues could be attributed to the increased
activity of GnT-V, which competes for substrate with GnT-III
and is associated with the consequential elevated level of
branched N-glycans.
doi: 10.1371/journal.pone.0072704.g007
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purification (upper profiling), with relatively simple purification
(middle profiling) and optimal purification (lower profiling).
(TIF)
Figure S3.  The exoglycosidase sequencing of N-glycans
of membrane proteins from breast cancer cell line T47D.
Arrow lines indicate the changes of glycan peaks due to
glycosidase digestion. The nomenclature of N-glycans and
symbolic representations correspond to that in Figure 2.
(TIF)
Table S1.  The pearson correlation coefficient between
specific N-glycans and clinical pathological features.
(DOC)
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